O-021 Levothyroxine in Euthyroid Thyroid Peroxidase Antibody positive Women with Recurrent Pregnancy Loss: a multicentre, randomised, double-blind trial (T4LIFE trial)
Abstract:Study question
Does levothyroxine treatment increase live birth rates in thyroid peroxidase antibodies (TPO-Ab) positive women with recurrent pregnancy loss (RPL) and normal thyroid function?
Summary answer
Levothyroxine treatment did not result in higher live birth rates in women with RPL positive for TPO-Ab and a normal thyroid function, compared to placebo.
What is known al… Show more
“…Compared with placebo, levothyroxine treatment did not result in higher live birth rates (defined as birth of a living fetus > 24 weeks' gestation). 11 Findings from both the TABLET study and the T4Lifetrial support that the use of levothyroxine is not beneficial to prevent miscarriage in women with recurrent pregnancy loss who are euthyroid and positive for TPO-Ab. 10,11 The 2017 ATA guidelines provide evidence-based recommendations for clinicians caring for pregnant women with thyroid conditions.…”
Section: Thyroid Autoantibodies and Miscarriagementioning
confidence: 98%
“…11 Findings from both the TABLET study and the T4Lifetrial support that the use of levothyroxine is not beneficial to prevent miscarriage in women with recurrent pregnancy loss who are euthyroid and positive for TPO-Ab. 10,11 The 2017 ATA guidelines provide evidence-based recommendations for clinicians caring for pregnant women with thyroid conditions. The guidelines note that there is not enough evidence to convincingly determine a beneficial impact of levothyroxine administration on the reduction of pregnancy loss in newly pregnant TPO-Ab-positive euthyroid women with a history of pregnancy loss.…”
Section: Thyroid Autoantibodies and Miscarriagementioning
In this review, the authors discuss the current evidence related to adverse pregnancy outcomes in women with thyroid autoantibodies who are euthyroid, describing management strategies and screening approaches for thyroid disorders during pregnancy.
“…Compared with placebo, levothyroxine treatment did not result in higher live birth rates (defined as birth of a living fetus > 24 weeks' gestation). 11 Findings from both the TABLET study and the T4Lifetrial support that the use of levothyroxine is not beneficial to prevent miscarriage in women with recurrent pregnancy loss who are euthyroid and positive for TPO-Ab. 10,11 The 2017 ATA guidelines provide evidence-based recommendations for clinicians caring for pregnant women with thyroid conditions.…”
Section: Thyroid Autoantibodies and Miscarriagementioning
confidence: 98%
“…11 Findings from both the TABLET study and the T4Lifetrial support that the use of levothyroxine is not beneficial to prevent miscarriage in women with recurrent pregnancy loss who are euthyroid and positive for TPO-Ab. 10,11 The 2017 ATA guidelines provide evidence-based recommendations for clinicians caring for pregnant women with thyroid conditions. The guidelines note that there is not enough evidence to convincingly determine a beneficial impact of levothyroxine administration on the reduction of pregnancy loss in newly pregnant TPO-Ab-positive euthyroid women with a history of pregnancy loss.…”
Section: Thyroid Autoantibodies and Miscarriagementioning
In this review, the authors discuss the current evidence related to adverse pregnancy outcomes in women with thyroid autoantibodies who are euthyroid, describing management strategies and screening approaches for thyroid disorders during pregnancy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.